~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2
Parts of the World Seeing New COVID-19 Variant
HHS, NIH Unveil Vaccine Initiative to Protect Against Future Pandemics
Hospital-Onset SARS-CoV-2 Infection During Omicron Linked to Morbidity
About Half Have Meaningful Drop in Long COVID Symptoms by 36 Months
Genetic Screening Can ID Hemoglobinopathy Prevalence
Few Meet Major Clinical Response Criteria After Treatment Escalation for Lupus
Nonpharmacologic Therapy Cuts Opioid Use Disorder Risk With Low Back Pain
~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2 
Parts of the World Seeing New COVID-19 Variant 
HHS, NIH Unveil Vaccine Initiative to Protect Against Future Pandemics 
Hospital-Onset SARS-CoV-2 Infection During Omicron Linked to Morbidity 
About Half Have Meaningful Drop in Long COVID Symptoms by 36 Months 
Genetic Screening Can ID Hemoglobinopathy Prevalence 
Few Meet Major Clinical Response Criteria After Treatment Escalation for Lupus 
Nonpharmacologic Therapy Cuts Opioid Use Disorder Risk With Low Back Pain 
